MiNK Therapeutics Outlines Phase II ARDS Trial with Initial Data Expected in Late 2026

MiNK Therapeutics (NASDAQ: INKT) announced a randomized Phase II trial for acute respiratory distress syndrome (ARDS), involving 90 patients, with initial data expected by the end of 2026. The company highlighted recent scientific presentations and ongoing clinical progress in oncology and pulmonary indications.

By SA Transcript Insights Editor, SA News Editor · Seeking Alpha · May 15, 2026, 20:51 UTC

Tickers: $INKT

Topics: biotech clinical data oncology pulmonary indications

Read the full article at Seeking Alpha

More World news

U.S. Trade Representative Jamieson Greer to Discuss Tariff Policies and Export Controls CNBC · November 12, 2026, 13:31 UTC
Coinbase CEO Brian Armstrong Discusses Binance Hack and Political Shifts Impacting Crypto CNBC · November 12, 2026, 13:44 UTC
Tradeify Announces Multi-Year Partnership with Inter Miami CF PR Newswire · November 12, 2026, 14:15 UTC
Bain & Company Report: AI to Reshape Banking Competition and Market Leadership PR Newswire · November 12, 2026, 14:15 UTC
Tradeify Announces Multi-Year Partnership with Inter Miami CF PR Newswire · November 12, 2026, 14:15 UTC
Tradeify Announces Multi-Year Commercial Partnership with Inter Miami CF PR Newswire · November 12, 2026, 14:15 UTC
Jensen Huang's Nvidia Stake Complicated by Joint Ownership with Spouse Following Resignation CNBC · November 12, 2026, 14:13 UTC
Vanguard Launches Vanguard Emerging Markets Bond Active ETF (VEMB) PR Newswire · November 12, 2026, 14:10 UTC
Nvidia CEO Jensen Huang Resigns Amid National Security Concerns; Colette Kress Appointed Interim CEO TechCrunch · November 12, 2026, 14:10 UTC
Vecima Networks Reports Q1 Revenue Growth of 37.4% with Non-GAAP EPS of $0.29 Seeking Alpha · November 12, 2026, 14:04 UTC